Skip to main content
Premium Trial:

Request an Annual Quote

Abraham Tzou

Freenome has appointed Abraham Tzou as its VP of regulatory affairs. Tzou will be in charge of regulatory strategy for products developed by Freenome and manage submissions to the US Food and Drug Administration and oversight bodies abroad.  

Tzou joins Freenome after serving as a medical officer at the FDA's Center for Devices and Radiological Health, where he led the clinical evaluation of in vitro diagnostics for cancer screening and prognosis, genetic disorders, and companion tests. During his tenure at the agency, he received commendation for his part in a team that reviewed Exact Sciences' non-invasive, colon cancer screening test Cologuard for parallel review. 

Freenome is developing a non-invasive cancer screening technology that involves genome-wide sequencing and a computational system, called Adaptive Genomics Engine. The company is interested in pursuing Parallel Review for this technology, which if successful, would enable simultaneous FDA approval and a national coverage determination from the Centers for Medicare & Medicaid Services.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.